Title: Treating degenerative disc disease with harvested disc cells and analogues of the extracellular matrix
United States Patent: 6,340,369Inventors: Ferree; Bret A. (1238 Cliff Laine Dr., Cincinnati, OH 45208)
Appl. No.: 638726Filed: August 14, 2000
Living intervertebral disc cells are harvested, cultured and combined with type-specific collagen-glycosaminoglycan extracellular matrix analogues to restore disc function and eliminate pain in patients with disc disease. In the preferred embodiment, the engineered disc tissue is morselized to allow insertion through a small puncture in the annulus fibrosis with a needle and syringe. Additional therapeutic substances such as culture medium, growth factors, differentiation factors, hydrogels polymers, antibiotics, anti-inflammatory medications, or immunosuppressive medications are disclosed as additives to the engineered disc tissue.
SUMMARY OF THE INVENTION
This invention resides in a method of treating a diseased or traumatized
intervertebral discs using natural, engineered tissue as opposed to
synthetic materials. Broadly, live, intervertebral disc cells are
harvested from a patient, cultured, and transplanted while still viable
into the affected disc. In the preferred embodiment, the cultured cells
are transferred and grown on an analogue of the extracellular matrix to
yield an engineered disc tissue. Collagen-glycosaminoglycans preferably
provide the extracellular matrix, though existing alternative and
yet-to-be-developed analogues may be substituted.
Claim 1 of 35 Claims